What question did this study set out to answer?

To evaluate the rationale and clinical evidence for intraperitoneal carboplatin in ovarian cancer treatment.

February 28, 2026Cancers0 citationsOpen Access

The New Era of Intraperitoneal Carboplatin in Ovarian Cancer: From Biological Rationale to Clinical Implementation

SNShoji NagaoOkayama University AFAtsushi FujikawaOkayama University YTYui TanakaOkayama University

Key Points

To evaluate the rationale and clinical evidence for intraperitoneal carboplatin in ovarian cancer treatment.
Reviewed existing literature on intraperitoneal carboplatin and its use in ovarian cancer.
Analyzed the findings from the iPocc trial and compared them with GOG-252.
Discussed implications for patients with minimal residual disease and those undergoing neoadjuvant chemotherapy.
Intraperitoneal carboplatin shows improved tolerability compared to cisplatin-based regimens.
Emerging evidence supports its use beyond minimal residual disease contexts.
The review suggests strong potential for incorporating IP carboplatin into maintenance therapy.

Abstract

Epithelial ovarian cancer is predominantly characterized by peritoneal dissemination, providing a strong biological rationale for intraperitoneal (IP) chemotherapy. Although IP cisplatin-based regimens have demonstrated substantial survival benefits in pivotal randomized trials, toxicity and catheter-related complications limit their widespread adoption. IP carboplatin has emerged as a pragmatic alternative with improved tolerability while preserving its pharmacokinetic advantages. This review summarizes the biological and pharmacological rationale for IP carboplatin and critically examines the clinical evidence, with a particular emphasis on the Intraperitoneal Carboplatin for Ovarian Cancer (iPocc) trial and its divergence from Gynecologic Oncology Group (GOG)-252. We further discuss the potential applicability of IP carboplatin beyond the traditional setting of minimal residual disease, including patients undergoing neoadjuvant chemotherapy and interval debulking surgery, as well as its possible use in the contemporary era of maintenance therapy. Collectively, the accumulated evidence supports renewed consideration of IP carboplatin as a versatile component in modern ovarian cancer management.

AIに質問

Bookmark

View Full Paper

Cite This Study

Nagao et al. (Fri,) studied this question.

synapsesocial.com/papers/69a287f20a974eb0d3c03e0b https://doi.org/https://doi.org/10.3390/cancers18050764

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AIに質問

Bookmark

View Full Paper